Literature DB >> 1311685

Pharmacokinetics of rufloxacin in healthy volunteers.

G Segre1, D Cerretani, L Moltoni, R Urso.   

Abstract

The plasma and urine kinetics of rufloxacin were assessed in healthy volunteers after single (100, 200, 400 and 800 mg) and multiple (300 mg followed by 150 mg daily, Group 1, and 400 mg followed by 200 mg daily, Group 2) oral doses. The kinetics of a single oral dose of 800 mg was assessed in fasting and non-fasting subjects to assess the influence of food intake on drug absorption. The AUCs were 134, 266 and 375 micrograms.h.ml-1 after 100, 200 and 400 mg, respectively. The AUC after 800 mg p.o. was 715 micrograms.h.ml-1 in fasting subjects and 614 micrograms.h.ml-1 in non-fasting subjects. The parameters of the model and the mean renal clearance values indicated some departure from linearity in rufloxacin kinetics. After multiple doses the plasma drug levels during the 6th treatment day were similar to those after the first dose in Group 1 and were about 30-40% higher after the first dose in Group 2. The half-lives after the last dose were much shorter than those estimated in the single dose studies (33-36 h and 50-80 h, respectively).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311685     DOI: 10.1007/bf00314928

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

1.  Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.

Authors:  V Cecchetti; A Fravolini; R Fringuelli; G Mascellani; P Pagella; M Palmioli; G Segre; P Terni
Journal:  J Med Chem       Date:  1987-03       Impact factor: 7.446

2.  A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics.

Authors:  G Segre; D Cerretani; D Cerri; L Moltoni
Journal:  Drugs Exp Clin Res       Date:  1988
  2 in total
  1 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.